傲農生物(603363.SH):控股股東、實控人質押的1773.85萬股延期購回
格隆匯6月16日丨傲農生物(603363.SH)公佈,公司近日收到控股股東傲農投資、實際控制人吳有林關於辦理部分股份質押延期購回的通知,其中,傲農投資延期購回921.7萬股,吳有林延期購回852.15萬股,延期購回後質押到期日均為2021年12月10日。
截至2021年6月15日,傲農投資、吳有林及其一致行動人吳有材、傅心鋒、張明浪、郭慶輝累計質押公司股份184,388,395股,佔實際控制人及其一致行動人合計持股的54.85%,佔公司總股本的26.90%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.